Two roads for oncolytic immunotherapy development

Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) administration. While this may allow easy access to metastatic lesions, there is limited data s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Howard L., Bommareddy, Praveen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359832/
https://www.ncbi.nlm.nih.gov/pubmed/30709365
http://dx.doi.org/10.1186/s40425-019-0515-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359832/
https://www.ncbi.nlm.nih.gov/pubmed/30709365
http://dx.doi.org/10.1186/s40425-019-0515-2

Ejemplares similares